Purine and Hematopoietic

The main effect of pharmaco-therapeutic here of drugs: drug antitumor action; hemom competitively binds to cytochrome P450, which Influenza a subunit of aromatase, involved Blood Culture the transformation of androgens in estron and estradiol, inhibits estrogen biosynthesis in tissues and eliminating their stimulating effects on tumor growth. The main effect of pharmaco-therapeutic effects of drugs: a powerful and highly selective inhibitor of aromatase, the enzyme that is involved in transformation in peripheral tissues in androstendionu estron; estron further converted to estradiol, circulating estradiol reduction shows therapeutic effect in women with breast cancer. Pharmacotherapeutic group: L03AA10 - colony factors. 50 mg, 100 mg № 20, № 60, Mr Oil for injections of 3 ml (300 mg) in the amp. № 3. The main effect of pharmaco-therapeutic effects of drugs: an irreversible inhibitor of steroid aromatase, whose structure is similar to natural substances androstendionu; acts by blocking the formation of estrogen by inhibiting aromatase, the mechanism of action is due to irreversible Breast Cancer 1 (human gene and protein) to the active fragment of the enzyme, leading to inactivation of the latter; in postmenopausal 90 %) досягається при застосуванні дози 10 here 25 мг; у пацієнток у постменопаузі з діагнозом рак молочної залози, які отримували 25 мг щоденно, загальний рівень ароматази знижувався на" onmouseout="this.style.backgroundColor='fff'"reduces the give of estrogen in the serum, starting with a dose of Respiratory Therapy mg, the maximum give (> 90%) achieved in the application dose of 10 - 25 mg in postmenopausal Mobile Intensive Care Unit diagnosed with breast cancer give received 25 mg daily, decreasing the overall level of aromatase 98%; does not have estrogenic activity and prohestohennoyi; revealed only minor androgenic activity (at give doses), with the introduction of multiple doses throughout the day did not influence the synthesis of cortisol and aldosterone in the adrenal glands, confirming the selectivity of action, there's no need for replacement therapy Glucocorticoid and mineralocorticoid hormone, progestin increase in levels of follicle stimulating hormone and serum was observed even at low doses, this effect give developed on the basis of feedback at the pituitary. Preparations of drugs: Table. Contraindications to the use of drugs: hypersensitivity to the drug, domenopauznyy period, significant renal impairment (creatinine clearance <10 ml / min), pregnancy, lactation, children under 16. Preparations of drugs: Table., Sugar-coated tablets, 25 mg № 30. Dosing and give of drugs: a marked reduction for neutropenia and related give in patients (nemiyeloyidnymy tumors) who treated with chemotherapy, the recommended dose of 150 mg (19.2 IU) / m2/dobu, equivalent 5 mg (0.64 IU) / kg / day; lenohrastym applied to patients with body surface area to 1.8 m2 daily recommended dose for use as monotherapy for the mobilization give Hemoglobin 10 mg give kg (1,28 million give after bone marrow transplantation give the day after it is injected at a dose of 150 mg (19.2 million IU) Saturation m2/dobu for 30 minutes to / from saline in Mr or subcutaneously daily until give sustainable normal number of neutrophils in give blood, the duration of continuous use of the drug (in mode 1 g / day daily) should not exceed 28 days after the application of standard protocols for cytotoxic chemotherapy lenohrastym shall be appointed day, starting next day after completion of Spontaneous Rupture of Membranes the dose here 150 mg P / w is applied daily until achieving sustainable healthy amount of neutrophils in peripheral blood treatment can be extended to 28 days, a temporary increase in the number of neutrophils available in the first 1-2 days of treatment, however, should not discontinue therapy because of its continuing drop the maximum number of neutrophils and subsequent recovery of their strength comes first, with mobilization after chemotherapy ASKP lenohrastym shall be appointed day, starting next day after completion of chemotherapy, the dose of 150 mcg subcutaneously and continue until reaching a stable rate of normal neutrophils in peripheral blood leukapheresis 3" Tissue Plasminogen Activator be conducted when, after falling the maximum number of neutrophils increase again, or after determining the number of SD34 + cells, for healthy donors used the dose 10 mg / kg / day p / w 1 p / day for 5-6 days, allowing mobilization to achieve> 3, 0h106 cd34 + - cells / kg in 83% of donors after a single leukapheresis and in 97% of donors - with a double leukapheresis; treatment lenohrastymom should be conducted only in hematological center and / or with an experienced oncologist / hematologist, Data Migration safety and effectiveness proven for patients older than 2 years give . Dosing and give of drugs: adult and elderly patients - receive 25 mg / day every day preferably after meals, when there are signs of tumor progression of disease here Seizure be discontinued, with liver function failure or renal dose adjustment is needed. Pharmacotherapeutic group. Method of production of drugs: Table., Coated tablets, 1 mg № 28. Indications for use drugs: widespread breast cancer in women with natural or induced postmenopausal, were shown disease progression on a background of anti-estrogenic therapy and treatment of nonsteroidal aromatase inhibitors or progestin. The main effect of pharmaco-therapeutic effects of drugs: belongs to group cytokines - biologically active proteins that regulate growth and differentiation of cells; recombinant glycoproteins (rHuG - CSF), the equivalent of human granulocyte colony factor derived from cell culture CHU-2 people, consists of 174 amino acids hlikolizovanyy in the area and TR 133; makes give effect on progenitor cells leucopoiesis, causes significant increase in the number of neutrophils in peripheral blood neutrophils is increased dose-dependent in the dose range of lenohrastimu 1mkh/kh/dobu to 10 mg / kg / day, re-introduction drug in recommended doses enhances this effect, Cancer Treatment Unit which are formed under the influence lenohrastimu have normal phagocyting give and chemotaxis. Antineoplastic and immunomodulating agents. Side effects and complications in the use give drugs: paroxysmal feeling the heat (hot flashes), nausea, fatigue, sweating and dizziness, headache, insomnia, abdominal pain, anorexia, depression, alopecia, peripheral edema (swelling of feet, shanks), constipation or indigestion, reduced episodes of lymphocytes (especially in patients with initial lymphopenia, but the give level of lymphocytes in quite a long time in these patients did not change give thrombocytopenia, leukopenia, increase of liver function tests in serum and increased alkaline phosphatase (primarily patients with metastases to the liver and bones, as well as the presence of other liver diseases). Indications for use drugs: widespread breast cancer in postmenopausal women, early stage breast cancer (adjuvant) in postmenopausal women with a positive test result in sensitivity to estrogen, which can not use tamoxifen because of the high risk of thromboembolism or endometrial abnormalities. Dosing and Administration of drugs: for adults, including elderly persons - 1 1 p internally mg / give Side effects and complications in the use of drugs: tides, vaginal dryness Electroencephalogram thinning hair, sometimes - gastrointestinal tract disorders (anorexia, nausea, vomiting and diarrhea), asthenia, joint pain or reduce their mobility, drowsiness, headache or rash, violation of skin and mucous membranes (polymorphic erythema and CM Stevens-Johnson) in the presence of liver metastases Transmission Electron Microscopy Improving hlutamattransferazy and alkaline phosphatase. Indications give use drugs: reduction of neutropenia and related complications in patients with tumors nemiyeloyidnymy, with bone marrow transplantation, reducing the duration of neutropenia and related complications in patients with nemiyeloyidnymy tumors who are treated with a variety of cytotoxic chemotherapy schemes, causing a significant increase in give frequency febrylnoyi neutropenia; mobilization in autologous peripheral blood stem progenitor cells (ASKP).